Targeting HER2 in Advanced NSCLC: Translating Evidence Into Equitable, Personalized Care for Veterans

This continuing education activity focuses on the diagnosis, risk stratification, and treatment of HER2-altered advanced non-small cell lung cancer (NSCLC) in the Veterans Health Administration system. Healthcare professionals will learn about comprehensive genomic profiling interpretation, emerging HER2-targeted therapies, recent clinical trial results, guideline updates, and strategies for addressing social determinants of health and shared decision-making to improve patient outcomes and quality of life.